ATOMS device shows efficacy in treating male stress urinary incontinence

NewsGuard 100/100 Score

In the largest study yet to assess the long-term safety and efficacy of the adjustable transobturator male system (ATOMS) to treat incontinence in men following invasive prostate treatment, the overall success and dry rates were 90% and 64%, respectively, after a median of 31 months.

Due to the all-time adjustability in the outpatient setting and the fixed anchoring that prevents dislocation, the ATOMS device has major advantages compared with other minimally invasive male sling options. The last generation with the small and undisturbing pre-attached full silicon-covered scrotal port system showed excellent results with short operating time (median 26 minutes) and ease of implantation.

Daily pad test and pad use decreased from a median of 400ml and 4 to a median of 18ml and 1. Concomitantly, life quality ratings significantly improved and changed to a high level of satisfaction.

"Due to this recently published data, the ATOMS continence device will play a main role in treating male stress urinary incontinence in the future," said Dr. Alexander Friedl, lead author of the BJU International study.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nanobots for bladder cancer treatment, promising high efficacy and targeted delivery